IDH2 and acute myeloid leukemia: Thus, for IDH1-mutant AML, one may consider using IDH1-inhibitors rather than HMA + VEN, while for the IDH2-mutant disease, perhaps the use of HMA + VEN may be more likely to offer clinical benefits.